Quest Diagnostics [DGX] vs Idexx Laboratories [IDXX] Detailed Stock Comparison
Quest Diagnostics
NYSE
Loading...
Idexx Laboratories
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Quest Diagnostics wins in 9 metrics, Idexx Laboratories wins in 10 metrics, with 0 ties. Idexx Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Quest Diagnostics | Idexx Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 21.50 | 52.42 | Quest Diagnostics |
| Price-to-Book Ratio | 2.78 | 34.68 | Quest Diagnostics |
| Debt-to-Equity Ratio | 86.90 | 84.81 | Idexx Laboratories |
| PEG Ratio | 0.96 | 1.07 | Quest Diagnostics |
| EV/EBITDA | 12.75 | 37.03 | Quest Diagnostics |
| Profit Margin (TTM) | 9.03% | 24.41% | Idexx Laboratories |
| Operating Margin (TTM) | 15.32% | 33.62% | Idexx Laboratories |
| EBITDA Margin (TTM) | 15.32% | 33.62% | Idexx Laboratories |
| Return on Equity | 14.26% | 64.87% | Idexx Laboratories |
| Return on Assets (TTM) | 6.34% | 23.26% | Idexx Laboratories |
| Free Cash Flow (TTM) | $909.00M | $798.08M | Quest Diagnostics |
| 1-Year Return | 20.02% | 31.81% | Idexx Laboratories |
| Price-to-Sales Ratio (TTM) | 1.91 | 12.51 | Quest Diagnostics |
| Enterprise Value | $26.24B | $51.57B | Idexx Laboratories |
| EV/Revenue Ratio | 2.49 | 12.77 | Quest Diagnostics |
| Gross Profit Margin (TTM) | 34.15% | 62.62% | Idexx Laboratories |
| Revenue per Share (TTM) | $94 | $50 | Quest Diagnostics |
| Earnings per Share (Diluted) | $8.34 | $12.04 | Idexx Laboratories |
| Beta (Stock Volatility) | 0.56 | 1.58 | Quest Diagnostics |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Quest Diagnostics vs Idexx Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Quest Diagnostics | -0.50% | -5.51% | -2.25% | 2.56% | 8.59% | 18.20% |
| Idexx Laboratories | -0.54% | -0.44% | -3.84% | 15.07% | 65.65% | 53.55% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Quest Diagnostics | 20.02% | 41.49% | 48.44% | 173.00% | 254.45% | 263.40% |
| Idexx Laboratories | 31.81% | 93.38% | 48.15% | 751.80% | 1,915.99% | 3,848.30% |
News Based Sentiment: Quest Diagnostics vs Idexx Laboratories
Quest Diagnostics
News based Sentiment: MIXED
October saw Quest Diagnostics making strategic moves with key partnerships and expanding into growing testing areas like Alzheimer's. However, these positive developments were offset by concerns about the company's financial performance, particularly its negative operating income and the sustainability of its dividend, creating a mixed investment picture.
Idexx Laboratories
News based Sentiment: MIXED
IDEXX reported impressive Q2 results and raised guidance, indicating strong performance. However, a pending regulatory review, mixed adoption of a key product, and insider selling introduce uncertainty, creating a mixed investment narrative. The combination of positive and negative developments warrants a cautious yet optimistic outlook.
Performance & Financial Health Analysis: Quest Diagnostics vs Idexx Laboratories
| Metric | DGX | IDXX |
|---|---|---|
| Market Information | ||
| Market Cap | $20.82B | $50.50B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 922,270 | 397,460 |
| 90 Day Avg. Volume | 777,807 | 414,530 |
| Last Close | $178.43 | $627.78 |
| 52 Week Range | $146.17 - $191.49 | $356.14 - $688.12 |
| % from 52W High | -6.82% | -8.77% |
| All-Time High | $191.49 (Sep 30, 2025) | $706.95 (Jul 26, 2021) |
| % from All-Time High | -6.82% | -11.20% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.15% | 0.11% |
| Quarterly Earnings Growth | 0.23% | 0.45% |
| Financial Health | ||
| Profit Margin (TTM) | 0.09% | 0.24% |
| Operating Margin (TTM) | 0.15% | 0.34% |
| Return on Equity (TTM) | 0.14% | 0.65% |
| Debt to Equity (MRQ) | 86.90 | 84.81 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $64.54 | $18.20 |
| Cash per Share (MRQ) | $2.85 | $2.06 |
| Operating Cash Flow (TTM) | $1.68B | $905.81M |
| Levered Free Cash Flow (TTM) | $924.50M | $625.74M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Quest Diagnostics vs Idexx Laboratories
| Metric | DGX | IDXX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 21.50 | 52.42 |
| Forward P/E | 18.37 | 52.78 |
| PEG Ratio | 0.96 | 1.07 |
| Price to Sales (TTM) | 1.91 | 12.51 |
| Price to Book (MRQ) | 2.78 | 34.68 |
| Market Capitalization | ||
| Market Capitalization | $20.82B | $50.50B |
| Enterprise Value | $26.24B | $51.57B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.49 | 12.77 |
| Enterprise to EBITDA | 12.75 | 37.03 |
| Risk & Other Metrics | ||
| Beta | 0.56 | 1.58 |
| Book Value per Share (MRQ) | $64.54 | $18.20 |
Financial Statements Comparison: Quest Diagnostics vs Idexx Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DGX | IDXX |
|---|---|---|
| Revenue/Sales | $2.65B | $998.43M |
| Cost of Goods Sold | $1.79B | $375.05M |
| Gross Profit | $863.00M | $623.38M |
| Research & Development | N/A | $59.06M |
| Operating Income (EBIT) | $346.00M | $316.53M |
| EBITDA | $488.00M | $351.81M |
| Pre-Tax Income | $276.00M | $310.08M |
| Income Tax | $59.00M | $67.41M |
| Net Income (Profit) | $235.00M | $242.68M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DGX | IDXX |
|---|---|---|
| Cash & Equivalents | $188.00M | $163.97M |
| Total Current Assets | $2.08B | $1.32B |
| Total Current Liabilities | $1.44B | $1.14B |
| Long-Term Debt | $6.40B | $546.80M |
| Total Shareholders Equity | $7.04B | $1.45B |
| Retained Earnings | $9.49B | $5.58B |
| Property, Plant & Equipment | $2.75B | $833.62M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DGX | IDXX |
|---|---|---|
| Operating Cash Flow | $298.00M | $235.07M |
| Capital Expenditures | N/A | $-30.03M |
| Free Cash Flow | $197.00M | $207.94M |
| Debt Repayment | $-600.00M | N/A |
| Common Stock Repurchase | N/A | $-400.89M |
Short Interest & Institutional Ownership Analysis
| Metric | DGX | IDXX |
|---|---|---|
| Shares Short | 4.42M | 2.12M |
| Short Ratio | 6.10 | 5.41 |
| Short % of Float | 0.05% | 0.03% |
| Average Daily Volume (10 Day) | 922,270 | 397,460 |
| Average Daily Volume (90 Day) | 777,807 | 414,530 |
| Shares Outstanding | 110.62M | 81.60M |
| Float Shares | 111.24M | 79.12M |
| % Held by Insiders | 0.00% | 0.01% |
| % Held by Institutions | 0.99% | 0.97% |
Dividend Analysis & Yield Comparison: Quest Diagnostics vs Idexx Laboratories
| Metric | DGX | IDXX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |